Goldman Sachs’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
|
|||||
|
2024
Q2 | $41.7M | Buy |
|
|||||
|
2024
Q1 | $43M | Buy |
|
|||||
|
2023
Q4 | $22.6M | Buy |
|
|||||
|
2023
Q3 | $7.08M | Sell |
|
|||||
|
2023
Q2 | $11.6M | Sell |
|
|||||
|
2023
Q1 | $9.2M | Buy |
|
|||||
|
2022
Q4 | $9.68M | Buy |
|
|||||
|
2022
Q3 | $6.95M | Buy |
|
|||||
|
2022
Q2 | $2.67M | Buy |
|
|||||
|
2022
Q1 | $2.88M | Sell |
|
|||||
|
2021
Q4 | $13.7M | Sell |
|
|||||
|
2021
Q3 | $15M | Buy |
|
|||||
|
2021
Q2 | – | Sell |
|
|||||
|
2021
Q1 | $2.61M | Buy |
|
|||||
|
2020
Q4 | $469K | Buy |
|